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Perspectives on COVID-19 and palliative care research 
Back in April I wrote an editorial where I set out some of my hopes for palliative care in the context 
of the COVID-19 pandemic1. I hoped that palliative care would be seen as an important component 
of care for those with COVID-19, that we would be brave and bold in adapting to new situations, that 
we reach out to support people dying in all settings, that we maintain our humanity and compassion 
in providing care, and that palliative care research would be fundamental to informing our 
approaches to care. I think many of those hopes have been realised – I have been humbled and 
inspired many times by the way that palliative care has responded innovatively to needs created by 
the pandemic2, although remain frustrated that this is not always reflected in policy or funding 
decisions. Here, however, I primarily reflect from a researcher and editor perspective about how 
research has been highlighted as of fundamental importance during this pandemic.  
Certainly, in the UK, where I live, research – or certainly data – have been forefront in the public 
consciousness in a way that I do not remember seeing before. We are bombarded with information 
about vaccine trials, tests, positive cases, hospital usage statistics and deaths, including modelling, 
projections and their interpretation. We are told that policy is ‘following the science’.  There has 
been an explosion of research – over 8000 preprints are available on COVID-19 SARS-CoV-2 from 
medRxiv, for example. As a new disease it is obvious that research is needed to guide practice. Here 
at Palliative Medicine you can see all our COVID-19 papers collated in one place on our website 
(https://journals.sagepub.com/topic/collections-pmj/pmj-4-covid-19-articles/pmj). Examples of 
important research shared include information on optimal symptom management3, 4, on equity of 
access to care5, on possible palliative care need6, and on predicting mortality7.  With great support 
from our reviewers we are fast-tracking COVID-19 papers through our systems, and making them 
freely available when published.  
I argue that what is needed now is to briefly pause and take stock of where we are in terms of 
COVID-19 and palliative care research. The need for research in this area will not diminish, the virus 
is likely here to stay with us for quite some time. This is a moment for palliative care research to be 
visible and important, and we need to ensure that it remains relevant and robustly conducted. What 
are the key research questions that face us now and for the medium-term future? Questions that 
require attention are likely to include a consideration of when, to whom, and by which services 
palliative care should be offered. Effective approaches to symptom management and palliation, 
including palliative rehabilitation, for those with COVID-19 need to be further studied. We need a 
greater understanding of ‘Long COVID’ and how this might affect, if at all, the patients that we 
provide care for. We need to understand the longer-term impact of some of the service changes that 
we have had to adopt such as remote working, a shift to home care, and teleconsultation for all 
patients, whether with COVID-19 or not. What is impact of changes in provision on family carers 
both during care and in to bereavement. A focus on community and primary care settings may be 
particularly important given we know that there appear to be excess home deaths, and many 
patients may be reluctant to access in-patient care. In particular the experiences and voices of our 
patients have been challenging to understand in the short term, but need to be an integral part of 
research going forwards.  
For all research areas I believe that we need to focus on coordinated, joined up efforts. Much 
COVID-19 palliative care research to date has been small and local in scale and scope. This is not to 
denigrate this important research, and how teams responded rapidly, but large team or multi-
national research may reap greater benefits for the future in terms of transferrable knowledge that 
can influence practice. A health care example has been the RECOVERY trial here in the UK, focused 
on COVID treatments, that recruited 2,000 participants from 176 different hospitals within the first 
three months. Whilst perhaps not possible at this scope and scale, I argue that we need to be bold in 
our vision for how palliative care research can be planned and executed if we are to see maximum 
benefit for our patients.  
 
We also need to think about those conducting research, and how they are able to work effectively. 
We feared that the pandemic would have a negative impact on submissions to the journal, for 
example, due to the pressures of clinical care, the pausing of some research, and the general effect 
of restrictions such a home-based working or caring responsibilities. This hasn’t happened thus far, 
with more papers being submitted to the journal than ever before. It may be, however, that these 
effects will not be felt yet as papers submitted now are likely to be related to projects where data 
collection had already completed. A particular concern across the science community is the potential 
for these effects on research and research careers to affect women disproportionately8, with 
evidence emerging that they are less likely to be first authors on COVID related papers9. In many 
countries palliative care/research is female dominated, and our specialty might be particularly 
adversely affected by these issues. Whilst perhaps not as scientifically robust as these cited papers, 
we have looked at the gender of submitting authors to the journal from Jan-Oct 2019 and for the 
same time period in 2020. In 2019 66% of submitting authors were female, in 2020 this dropped to 
56%, with every month having a lower proportion of female submitting authors than in 2019.  A 
particular low point was in April 2020 when only 48% of papers had a female submitting author. It 
does therefore appear to be the case that the pandemic has had some effect on research or its 
dissemination amongst female colleagues. It is important that we think creatively about how we can 
be part of a system that enables and facilitates all research contributions if palliative care research 
overall is not to be particularly adversely affected.  
Here at Palliative Medicine we hope we can continue to play our part in effectively promoting and 
disseminating robust research. We have continued to grow and develop through the pandemic, 
albeit managing our own personal challenges of home-working, caring and clinical responsibilities 
that are affecting palliative care and research more generally. We welcome two new members to 
our Editorial Board, chosen through an open competitive process: Professor Lorna Fraser from York 
University in the UK who has a special interest in paediatric palliative care; and Dr Melissa Bloomer 
from Deakin University in Australia whose work focuses on palliative care in acute care settings. We 
have also welcomed new members of our Editorial Advisory Board from North America and Europe. 
As an international journal we are seeking further representation from a broader range of countries, 
and hope to continue to serve our international community of readers as well as possible in what 
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